StockRunway.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
New York, NY -- (SBWIRE) -- 01/27/2014 -- StockRunway.com issues special report on: Cloud Peak Energy Inc. (NYSE:CLD), Harmony Gold Mining Co. (ADR)(NYSE:HMY), Keryx Biopharmaceuticals (NASDAQ:KERX), Prana Biotechnology Limited (ADR)(NASDAQ:PRAN)
Cloud Peak Energy Inc. (NYSE:CLD) opened its shares at the price of $17.54 for the day. Its closing price was $18.05 after gaining +1.80% for the day. The company traded with the total volume of 1.36 million shares, while its average trading volume remained 711,712.00 shares. The beta of CLD stands at1.23. Cloud Peak Energy Inc., through its subsidiaries, engages in the coal mining operations in the Powder River Basin (PRB) and the United States. It produces and sells sub-bituminous thermal coal with low sulfur content primarily to electric utilities.
For How Long CLD will Fight for Profitability? Read This Trend Analysis report
Harmony Gold Mining Co. (ADR)(NYSE:HMY) percentage change surged +1.73% to close at $2.94 with the total traded volume of 4.56 million shares, and average volume of 2.77 million. The 52 week range of the stock remained $2.35 - $7.30, while its day lowest price was $2.87 and it hit its day highest price at $3.01. Harmony Gold Mining Company Limited is engaged in the exploration, extraction, processing, and smelting of gold in South Africa and Papua New Guinea. The company also explores for uranium, silver, copper, and molybdenum.
For How Long HMY’s Gloss will Attract Investors? Find out via this report
Keryx Biopharmaceuticals (NASDAQ:KERX) started its trading session with the price of $15.44 and closed at $15.70 by scoring +1.62%. KERX’s stocks traded with total volume of 5.52 million shares, while the average trading volume remained 3.06 million shares. The beta of KERX stands at 3.92. Day range of the stock was $15.24 -$15.84. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States.
Will KERX Continue To Move Higher? Find Out Here
Prana Biotechnology Limited (ADR)(NASDAQ:PRAN) ended its day with the gain of +1.58% and closed at the price of $8.99 after opening at $8.50. Stock traded during its last trading session with the total volume of 1.27 million shares, as compared to its average volume of 701,839.00 shares. Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. It primarily focuses on the Alzheimer’s, Parkinson?s, and Huntington’s diseases, as well as various cancer and age-related macular degeneration.
Why Should Investors Buy PRAN After The Recent Gain? Just Go Here and Find Out
StockRunway.com is an Elite Financial Stock website catering to individual investors, fund managers, investment bankers and equity analysts. Whether you're new to penny stocks or a seasoned veteran, you'll find all the information you will need right here! Our research is a remarkable educational tool for everyone to utilize.
Sign up TODAY and join the vast amount of investors already benefiting from the best free alerts from StockRunway's service today!
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site, Press Releases or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Read our Full Disclaimer by visiting our website.
Read Our Full Disclaimer at: http://www.stockrunway.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)